Sepsis is both a common and, despite present-day therapy, a serious disease. The pathophysiology of the septic response is a complex, multifactorial phenomenon which in part involves the activation of complement by bacterial endotoxin. A monoclonal antibody to human complement factor B, code-named lH5, which was capable of specifically inhibiting the alternative pathway of complement activation at concentrations as low as 1 ,ug/ml, is described. This agent had no effect on the classical pathway of complement activation. It was capable of preventing the activation of complement by even high concentrations (0.1 mg/ml) of whole endotoxin; however, it was ineffective in preventing activation of complement by endotoxin derived from a rough mutant. This agent could potentially be used in the treatment of sepsis.
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Sepsis is a systemic inflammatory response syndrome caused by the products of infection, particularly gram-negative bacteria. It is characterized initially by hyperdynamic shock resulting from a profound decrease in systemic vascular resistance. Subsequently, perturbations of the lungs, heart, kidneys, liver, and coagulation cascade can result in multiple organ failure. Sepsis is both a common and, despite present-day therapy, a serious disease, with 425,000 reported cases and approximately 100,000 deaths in the United States last year (34) .
It is generally acknowledged that the initial pathophysiologic event in most cases of sepsis is the introduction of the lipopolysaccharide endotoxin from the outer cell walls of gram-negative bacteria into the patient's circulation. Animals (22) and humans (47) inoculated with endotoxin develop a hyperdynamic state similar to early sepsis. In addition, 43% of the patients with clinical septic shock have detectable endotoxemia (13) .
There are many endotoxin-induced mediators of sepsis. One important mediator is the complement cascade, especially the anaphylatoxin C5a. The complement system may act alone or in conjunction with other mediators such as tumor necrosis factor (24) . There are three pieces of evidence that complement activation participates in the pathophysiology of sepsis. First, complement activation occurs in sepsis. Bacteremic patients have been shown to have decreased serum C3 concentrations (15, 33) and increased serum C5a concentrations (6) . In the latter case, the elevation of CSa correlated with clinical severity. Second, complement activation can mimic sepsis. Animals inoculated with homologous serum in which the complement had been activated by exposure to zymosan developed hyperdynamic shock similar to that found in septic patients (37, 44) . Finally, prevention of the formation of C5a mitigates sepsis. Animals who either were congenitally deficient in C5 or were treated with antibody to CSa were less likely to develop hyperdynamic shock when inoculated with endotoxin than were normocomplementemic controls (24, 46) .
Because of the apparent involvement of the complement cascade in endotoxin-mediated sepsis, a theoretic treatment of sepsis would be the blockade of complement activation at a point prior to the formation of CSa. This could be done by blocking the activation of C3, the initial protein in the terminal pathway. However, this would deprive a patient of the ability to combat a bacterial infection via the antibody-mediated classical pathway of complement activation. Although it is controversial, there is evidence that complement activation by endotoxin is mediated by the alternative pathway (15, 20, 21, 26 (23, 32, 50) .
The avidity of each otFB MAb was determined by performing the above-described aFB MAb ELISA with 10-1 to 10-7 M concentrations of mouse IgG (see below for the assay of mouse IgG). A plot of the concentration of IgG ([Ab]) versus the optical density (OD) produced a sigmoid curve which could be described by the equation
where maximum OD, 3, and -y were constants (40) . The incubated at 37°C for 480 min. At 30-min intervals, 10-,ul aliquots were removed from the mixture and chelated by the addition of EDTA to a final concentration of 56 mM in order to stop all magnesium-and calcium-dependent complement activation. The concentrations of native C3 (i.e., undegraded C3) in these aliquots as percentages of that found in undiluted NHS were determined by radial immunodiffusion as described in Materials and Methods. The amount of C3 breakdown was determined by comparing the native C3 concentrations in the initial aliquots and subsequent aliquots. None of the oaFB MAb preparations showed any ability to cause loss of C3. This is consistent with these IgGs existing as monomers which would lack the multiple proximate Fc domains required for classicalpathway complement activation (30) .
aFB MAb 1H5 blocked alternative-pathway complement activation. NHS was mixed with equal volumes of each aFB MAb preparation (final murine IgG concentration of 150 ,ug/ml) or of TS and incubated at 37°C for 20 min. Subsequently, zymosan, an activator of the alternative pathway, was added to a final concentration of S mg/ml and the mixtures were again incubated at 37°C for 30 min. The percent activation of C3 was measured by assaying the loss of native C3 in the samples incubated with zymosan compared with the loss in zymosan-free controls by radial immunodiffusion. Only one of the aFB MAbs, the one code-named 1H5, was able to inhibit the activation of complement by zymosan (C3 loss: TS control, 53.6% ± 2.2%; lH5, 2.4% ± 3.3%; 3F1, 54.4% ± 2.2%; 5G7, 53.6% ± 2.2%; and 7C3, 54.4% ± 2.2%; n = 5 for all groups; analysis of variance with Fisher least significant difference test, P < 0.0001).
Subsequently, a similar incubation was performed with varying concentrations of aFB MAb 1H5 as shown in Fig. 1 . Inhibition of activation was first seen at an atFB MAb 1H5 concentration of 1 ,ug/ml (third point in Fig. 1 ), and 100% inhibition was seen at approximately 25 ,ug/ml. These data were fitted to the asymptotic model y = a(1 -e-bx) by nonlinear regression analysis, and the dose of aFB MAb 1H5 required to produce 50% inhibition was found to be 6.11 ± 1.20 ,ug/ml. preparation, diluted in TS to achieve the appropriate concentration of the MAb, and incubated at 37°C for 20 min. Subsequently, zymosan was added to a final concentration of 5 mg/ml and the mixture was again incubated at 37°C for 30 min. The activation of the complement cascade was measured by assaying the production of C3a des arg by in the NHS incubated with both cLFB MAb 1H5 and zymosan, in NHS incubated with zymosan alone (zymosan controls), and in fresh serum (NHS controls) by radioimmunoassay. The curve shown is the nonlinear regression analysis best fit of the asymptotic modely = a(1 -e-r) with a 50% effective dose of 6.11 ± 1.20 ,ug/ml (P < 0.005).
aFB MAb 1H5 had no eflect on classical-pathway complement activation. NHS was mixed with an equal volume of a preparation of otFB MAb 1H5 (final murine IgG concentration of 150 ,ug/ml) and incubated at 37°C for 20 min. The hemolytic titer of this NHS mixture, as well as that of control NHS incubated with TS, was measured as described in Materials and Methods. The hemolytic titer of the NHS-aFB MAb 1H5 mixture was 78.43 ± 11.66, compared with a titer of 85.36 ± 8.20 for the NHS-TS mixture (n = 8 for each group). Comparison using a two-tailed Student t test showed that there was no statistically significant difference between the two groups.
aLFB MAb 1H5 blockade of the alternative pathway prevented complement activation by whole endotoxin. NHS was initially incubated with aFB MAb 1H5, and subsequently various amounts of endotoxin derived from S. typhosa 0901 were added. This bacterium's endotoxin contains both a lipid A-containing core lipopolysaccharide and an O-polysaccharide domain, and it is therefore referred to as a whole endotoxin. The activation of the complement cascade was measured by the production of C3a des arg. As can be seen in Fig. 2A , the activation of the complement cascade, which occurred at 1 ,ug of added endotoxin per ml in the controls, was completely prevented by preincubation with aFB MAb 1H5. Figure 2B shows the same experiment done with endotoxin derived from the mutant S. minnesota R-595, which contains only the core lipopolysaccharide. Not only does aFB MAb 1H5 not prevent the activation of complement by this endotoxin, but it actually accentuates the degree of activation seen in the control. This Figure 2A shows the results of incubation with whole endotoxin derived from S. typhosa 0901. Figure 2B shows the results of incubation with endotoxin derived from S. minnesota R-595. Note that the scale of they axis in Fig. 2A is different from that in 2B. Log-linear regression analysis of these data showed statistically significant complement activation with increasing endotoxin levels in all samples except for the NHS-oLFB MAb 1H5-S. typhosa 0901 mixture.
results from the potentiation of the classical pathway noted when the alternative pathway of complement activation is blocked (20) .
DISCUSSION
As detailed in the Introduction, activation of the complement cascade, presumably by endotoxin, is involved in the pathophysiology of sepsis. This paper describes a MAb to hu'man FB, aFB MAb 1H5, which may be used to control this complement activation.
The complement cascade may be initiated via two pathways. The classical pathway involves antigen-antibody complexes and the complement proteins Clq, Clr, Cls, C2, and C4 to form a C3 convertase. The alternate pathway involves the complement proteins C3b (or spontaneously hydrated C3), properdin, factor D, and FB to form a C3 convertase. The C3 convertase from either pathway will catalyze the cleavage of C3 and initiate the subsequent activation of the terminal cascade. As one would predict, the aFB MAb 1H5 described in this paper blocks only the alternate pathway of complement activation. The other three aFB MAbs described in this paper failed to block the activation of the alternative pathway despite having affinities to human FB that are similar to that of crFB MAb 1H5. In three studies of ctFB MAbs, two MAbs which increased FB activity by stabilizing the alternative-pathway convertase (12) , one which increased FB activity by enhancing the binding of B to C3b (49), three which decreased FB activity by destabilizing the alternative-pathway convertase (12, 52) , and two which decreased FB activity by blocking the binding of FB to C3b (52) have been isolated. It is possible that oFB MAb 1H5, as opposed to the other aoFB MAbs described in this paper, bound to human FB in such a way as to block its binding to C3b, so as to accelerate the decay of the alternative-pathway convertase or so as to deform its tertiary structure in such a way as to make it inactive.
The endotoxins found in the outermost cell wall of gramnegative bacteria are complex molecules made up of a core lipopolysaccharide containing lipid A. This is covalently bound to a long, complex polysaccharide (0-polysaccharide). The exact structure of the endotoxin varies a great deal from one bacterial species to another. In particular, the size of the 0-polysaccharide can range from nonexistent to >106 Da. It has long been recognized that endotoxin is capable of activating the complement cascade. It was initially shown that endotoxin activated the alternative cascade (20) , presumably because the 0-polysaccharides prevent the inhibitory factor H from having access to spontaneously formed alternative-path-way C3 convertase (38) . It was subsequently shown that the lipid A portion of the endotoxin molecule was capable of activating the classical pathway of the complement cascade (35) . At the present time there is not universal agreement as to which of these pathways of complement activation is more significant in sepsis; however, there are several pieces of evidence which indicate that the alternative pathway is more important. First, in the previously cited study of complement levels in septic patients (15) , it was found that the decreased serum C3 levels correlated with similar decreases in the alternative-pathway protein FB, whereas there was no detectable decrease in any of the classical-pathway proteins. Second, in a series of studies by the same group (21, 26) , a Salmonella strain which could have the length of its O-polysaccharide varied by manipulations of its growth medium was described. These bacteria were assayed for their ability to bind C3 and to be killed in nonimmune serum. It was shown that C3 bound only to bacteria containing endotoxin molecules with long O-polysaccharides and that this binding occurred even in the presence of Mg2+-EDTA, which prevents classical-pathway activity. This is consistent with the theory that these bacteria activate complement only via the alternative pathway. This group further showed that when the lengths of the 0-polysaccharides on the bacteria were progressively diminished, the bacteria became more susceptible to being killed by nonimmune serum. This would indicate that the ability of bacteria to activate complement via the alternative pathway on their 0-polysaccharides conferred resistance to the bacteria. A simple explanation of this phenomenon would be that the long O-polysaccharides allow serum complement to be activated by the alternative pathway in a location remote from the actual bacterial cell wall, thereby protecting the bacteria from the membrane attack complex formed during complement activation. This would provide a teleologic explanation for the production of the O-polysaccharides by the bacteria and for the alternative pathway activation seen during bacterial infections.
Consistent with this interpretation, this paper shows that blockade of the alternative pathway of complement activation by aFB MAb 1H5 prevents complement activation by whole endotoxin but not by O-polysaccharide-deficient endotoxin.
These results indicate that with whole endotoxin derived from S. typhosa 0901, the alternative pathway is the exclusive activator of complement. If lipid A activation of the classical pathway was occurring, then complement activation would proceed despite the block in the alternative pathway.
Because of the involvement of complement activation in the pathophysiology of a variety of diseases, many groups have attempted to identify a "magic bullet" which would terminate the turnover of the complement cascade without affecting other important biologic processes.
Initial efforts focused on cobra venom factor, a 140-kDa protein derived from the venom of the cobra Naja naja. This protein is homologous to the C3c portion of C3 (53) , and, as such, it binds to FB, is cleaved by complement factor D, and allows the formation of an active C3 convertase (36) . As opposed to the C3 convertase formed by true C3, the cobra venom factor C3 convertase is resistant to the actions of the complement control proteins H and I. This allows the undampened in vitro and in vivo turnover of the complement cascade with a resultant depletion of serum complement (11, 29) . Cobra venom factor has never been attractive as a clinical tool, however, in large part because its mechanism of action, the promotion of the uncontrolled turnover of the complement cascade, leads to the release of C3a and C5a into the circulation (8) and causes hematologic abnormalities such as hemolysis, thrombolysis, and disseminated intravascular coagulation (5, 14) .
Attempts to inhibit the initiation of the complement cascade, rather than to push it to exhaustion as with cobra venom factor, have been made by producing substances which mimicked the structure of the proteins involved in complement activation to act as competitive inhibitors (3, 4, 7, 9, 18, 27, 42, 43, 48) . Although these attempts have met with some success, they have required very high concentrations of inhibitory substances ranging from 500 nM to 10,000,uM. As it would require gram amounts of these low-molecular-weight substances to produce such concentrations in the human extracellular fluid, these compounds are unlikely to be pharmacologically useful. The oFBMAb 1H5 described in this paper begins to inhibit complement activation at concentrations as low as 1 ,ug/ml. This level is clinically achievable, as it is similar to the concentrations of mouse IgG in serum seen with the antirejection drug OKT3 (16) . A potential limiting factor in the treatment of humans with any mouse IgG would be the presence of preformed human antibodies to mouse IgG, which would prevent the development of any therapeutic concentration in serum. Although these antibodies are rarely seen in patients who have not been previously treated with mouse IgG, they are seen in 20 to 85% of treated patients (19, 25) . A drawback to the treatment of sepsis with aFB MAb 1H5 would be the development of these blocking antibodies, which would limit further treatment with other mouse monoclonal agents.
Recently, a more successful attempt to obtain an effective inhibitor of complement activation was described by Weisman and coworkers (55) . They exploited an analog of the complement control protein complement receptor 1, a membrane protein which allows cells to bind to the activated complement proteins C3b and C4b (1, 41) . This analog, sCR1, was able to block the activation of both the classical and the alternate complement pathways in vitro at doses as low as 10 to 20 ,ug/ml, similar to the effective dose of aFB MAb 1H5. A theoretic disadvantage of sCR1 compared with aFB MAb 1H5 is that it does not selectively block the alternative pathway of the complement cascade. Although blockade of the classical pathway may be potentially advantageous in some clinical settings, in the treatment of sepsis it would have the drawback of hindering the host's ability to combat bacterial invasion by using specific antibacterial antibodies. An agent that blocked only the alternative pathway would prevent formation of C5a by endotoxin but would leave other complement-mediated defenses intact. It must be noted that blockade of the alternative pathway itself may interfere with the host's ability to defend itself from bacterial attack. Patients who have congenital deficiencies of the alternative pathway protein properdin have an increased incidence of meningococcal disease (45) . Further, there are no descriptions of persons with FB deficiencies, which may indicate that blockade of this protein has profoundly deleterious consequences.
In summary, this paper describes the derivation of aFB MAb 1H5 and demonstrates that it is a potent and specific inhibitor of the alternative pathway of complement activation.
It was further shown that by inhibiting the alternative pathway, aFB 1H5 is able to prevent the activation of complement by whole endotoxin. This agent has theoretic potential in the treatment of gram-negative sepsis. Future work will test the ability of aFB MAb 1H5 to blunt the cytokine response to endotoxin of immunopotent cells in tissue culture as well as its ability to mitigate the septic response in animal models. 
